n.a. (CADX)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Market Cap 1.25B
Div & Yield N.A. (N.A)

Latest News

SHAREHOLDER DEADLINE: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Cadence Pharmaceuticals, Inc. In Connection With The Sale Of The Company To Mallinckrodt Plc

SHAREHOLDER DEADLINE: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Cadence Pharmaceuticals, Inc. In Connection With The Sale Of The Company To Mallinckrodt Plc

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cadence Pharmaceuticals, Inc.

CADENCE PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

CADENCE PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

- Do you own shares of Cadence Pharmaceuticals, Inc. (NASDAQ GS: CADX)?

SHAREHOLDER DEADLINE: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Cadence Pharmaceuticals, Inc.

SHAREHOLDER DEADLINE: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Cadence Pharmaceuticals, Inc.

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Cadence Pharmaceuticals, Inc.

CADENCE INVESTOR ALERT: Faruqi & Faruqi, LLP Is Investigating Cadence Pharmaceuticals, Inc. (CADX) In Relation To The Proposed Sale Of The Company To Mallinckrodt Plc

CADENCE INVESTOR ALERT: Faruqi & Faruqi, LLP Is Investigating Cadence Pharmaceuticals, Inc. (CADX) In Relation To The Proposed Sale Of The Company To Mallinckrodt Plc

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Sale To Mallinckrodt Plc

Cadence Pharmaceuticals Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Sale To Mallinckrodt Plc

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Cadence...

Mallinckrodt Is Just One Of Dennis Kozlowski's Billion Dollar Babies

Mallinckrodt Is Just One Of Dennis Kozlowski's Billion Dollar Babies

Had you stuck with his stock after Kozlowski was charged in 2002 you might now be richly rewarded.

Law Firm Kirby McInerney LLP Investigating Potential Claims On Behalf Of Cadence Pharmaceuticals, Inc. Stockholders

Law Firm Kirby McInerney LLP Investigating Potential Claims On Behalf Of Cadence Pharmaceuticals, Inc. Stockholders

Kirby McInerney LLP is investigating potential claims against the Board of Directors of Cadence Pharmaceuticals, Inc.

CADENCE SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of Cadence Pharmaceuticals, Inc. Over The Proposed Sale Of The Company To Mallinckrodt Plc In A Cash Deal

CADENCE SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of Cadence Pharmaceuticals, Inc. Over The Proposed Sale Of The Company To Mallinckrodt Plc In A Cash Deal

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Cadence Pharmaceuticals, Inc.

Mallinckrodt Inks $1.3B Deal for Cadence

Mallinckrodt Inks $1.3B Deal for Cadence

Irish buyer offers a 26% premium to secure Cadence's Ofirmev injectable pain killer, which recently won approval in Canada.

Mallinckrodt Buys Cadence Pharma for $1.3 Billion

Mallinckrodt Buys Cadence Pharma for $1.3 Billion

Cadence sells an intravenous form of the painkiller acetaminophen used in hospitals.

Mallinckrodt Plc To Acquire Cadence Pharmaceuticals, Inc. For $14.00 Per Share, In Cash

Mallinckrodt Plc To Acquire Cadence Pharmaceuticals, Inc. For $14.00 Per Share, In Cash

Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceuticals company, and Cadence Pharmaceuticals, Inc.

Interesting CADX Put And Call Options For August 2014

Interesting CADX Put And Call Options For August 2014

Investors in Cadence Pharmaceuticals Inc saw new options become available this week, for the August 2014 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 229 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Biotech Stocks Partying Like It's 1999

Biotech Stocks Partying Like It's 1999

After a weak October, biotech stocks have rebounded in a big way in November. The sector is on pace for an history year of absolute and relative performance.

Interesting CADX Put And Call Options For January 2014

Interesting CADX Put And Call Options For January 2014

Investors in Cadence Pharmaceuticals Inc saw new options become available this week, for the January 2014 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CADX options chain for the new January 2014 contracts and identified one put and one call contract of particular interest.

Cadence Pharmaceuticals Recognized As A Top Workplace In San Diego Based On Employee Feedback

Cadence Pharmaceuticals Recognized As A Top Workplace In San Diego Based On Employee Feedback

Employee feedback through an anonymous survey included strong culture and employee engagement as top reasons to work for the company